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Introduction
Centrosomes are the major microtubule-organizing centers of 
animal cells and play an important role in organizing the inter-
phase cytoskeleton and poles of the mitotic spindle (Nigg, 2002). 
A single centrosome is comprised of a pair of centrioles sur-
rounded by an amorphous pericentriolar material, and centro-
some duplication is controlled by centriole replication (Loncarek 
and Khodjakov, 2009). In dividing cells, centrioles duplicate 
once per cell cycle adjacent to preexisting centrioles. Errors in 
this process lead to the production of an abnormal centro-
some number that can promote errors in spindle formation and 
subsequent chromosome missegregation (Ganem et al., 2009; 
Silkworth et al., 2009). Moreover, abnormalities in centrosome 
number are often observed in cancer cells; and thus, accurate 
control of centrosome number is critical for the maintenance of 
genome integrity (Nigg, 2006; Holland and Cleveland, 2009).
Centriole duplication is regulated by the conserved pro-
tein kinase Polo-like kinase 4 (Plk4; also known as SAK). 
Overexpression of Plk4 overrides the mechanism that limits 
centriole duplication, leading to multiple rounds of centriole 
duplication within a single cell cycle (Bettencourt-Dias et al., 
2005; Habedanck et al., 2005; Peel et al., 2007; Basto et al., 
2008). Plk4 is aberrantly expressed in human colorectal and 
liver cancer (Macmillan et al., 2001; Ko et al., 2005). Further-
more, Plk4+/ mice develop spontaneous liver and lung tumors 
(Ko et al., 2005), whereas overexpression of Plk4 promotes 
centrosome amplification and tumorigenesis in flies (Basto 
et al., 2008; Castellanos et al., 2008). Therefore, Plk4 activ-
ity must be precisely regulated to accurately control centriole 
duplication and prevent transformation.
Plk4 is a low abundance protein with a short cellular half-
life (Fode et al., 1996). Plk4 is ubiquitinated and degraded by 
the 26S proteasome (Fode et al., 1996; Cunha-Ferreira et al., 
2009; Korzeniewski et al., 2009; Rogers et al., 2009), and in-
hibiting proteasome function promotes centriole overduplica-
tion in a Plk4-dependent manner (Duensing et al., 2007). The 
SKP1–CUL1–F Box (SCF) complex is an E3 ubiquitin ligase 
comprised of three core subunits (Skp1, Cullin 1, and Rbx1) and 
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Plk4 (Fig. 1 A) were stably expressed in a human cell line 
(DLD-1) in which accurate chromosome segregation maintains 
a pseudodiploid karyotype (Lengauer et al., 1997). To facili-
tate direct comparison, WT and kinase-dead (KD) Plk4-EYFP 
transgenes were integrated at a predefined genomic locus in the 
host cell line using flippase (Flp) recombination target (FRT)/
Flp–mediated recombination. Plk4-EYFP expression was under 
tight tetracycline regulation, allowing temporal control of Plk4 
kinase-induced centriole biogenesis (Fig. S1, A and C). Previ-
ous work has shown that overexpressed Plk4KD can increase 
centrosome numbers in cycling populations of cells, whereas 
Plk4WT promotes centrosome amplification in S phase–arrested 
cells (Habedanck et al., 2005), suggesting dual pathways (one 
kinase dependent and another that is kinase independent) for 
Plk4 stimulation of centrosome duplication. Indeed, 48 h after 
induction of Plk4WT, 60% of asynchronously growing cells 
showed evidence of centriole amplification, whereas induction 
a variable F box protein that recognizes substrates only when 
they are phosphorylated at specific sites (Frescas and Pagano, 
2008). In Drosophila melanogaster cells, the SCF F box pro-
tein Slimb prevents centrosome amplification by ubiquitinating 
and promoting the degradation of SAK/Plk4 (Cunha-Ferreira 
et al., 2009; Rogers et al., 2009). A direct role of -TrCP (the 
vertebrate homologue of Drosophila Slimb) in promoting the 
destruction of Plk4 has not been demonstrated in vertebrates, 
although mouse cells lacking -TrCP have excess centrosomes 
(Guardavaccaro et al., 2003). In this study, we investigate the 
mechanism that limits Plk4 levels in vertebrates and show that 
Plk4 stability is regulated by its own kinase activity.
Results and discussion
To determine how mammalian Plk4 levels are established, 
EYFP-tagged wild-type (WT) and kinase-inactive (D154A) mouse 
Figure 1. Plk4 kinase activity destabilizes the protein. (A) Schematic of mouse Plk4, showing the location of the kinase domain, the Polo-box domain 
(PBD), and the cryptic Polo-box domain (Swallow et al., 2005). The locations of the AS and KD mutations are also shown. (B) Immunoblot showing the 
expression level of WT and KD Plk4-EYFP transgenes. (C) Titration showing the relative expression level of Plk4WT and Plk4KD. (D) Immunoblot showing the 
expression levels of Plk4WT, Plk4AS, and Plk4KD in the presence of DMSO or 1NM-PP1. (E) Immunofluorescence images acquired 48 h after Plk4-EYFP was 
induced with tetracycline. Cells were grown in DMSO or 1NM-PP1. Insets depict an enlargement of centrioles. Red, SAS-6; green, Plk4-EYFP; blue, DNA. 
Bars, 10 µm. (F) Graph quantifying of the proportion of cells with more than four centrioles 48 h after expression of Plk4-EYFP was induced. Cells were 
grown in the presence of either DMSO or 1NM-PP1. Bars represent the mean of at least three independent experiments with >300 cells per condition. 
Error bars represent the SEM.
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The 26 S proteasome inhibitor MG132 was added to 
Plk4WT- and Plk4KD-expressing cells to determine whether 
Plk4 kinase activity promotes proteasome-mediated Plk4 de-
struction. Plk4WT but not Plk4KD was substantially stabilized 
by MG132 treatment (Fig. 2 A). To determine whether kinase- 
active Plk4 is capable of destabilizing Plk4KD in trans, we in-
duced expression of Plk4WT-EYFP or Plk4KD-EYFP in cells con-
stitutively expressing Plk4KD-Myc. Expression of Plk4WT-EYFP, 
but not Plk4KD-EYFP, reduced the stability of Plk4KD-Myc, 
demonstrating that Plk4 can promote self-destruction through 
intermolecular phosphorylation (Fig. 2 B).
Our data support a model in which autophosphorylation 
triggers Plk4’s destruction to self-limit kinase activity. Plk4 
possesses a conserved SCF-TrCP phosphodegron, and previ-
ous studies in Drosophila cells have implicated a role of this 
two-phosphosite phosphodegron in regulating Plk4’s stability 
(Cunha-Ferreira et al., 2009; Rogers et al., 2009). Therefore, 
we considered the possibility that autophosphorylation (in cis 
or trans) of the -TrCP phosphodegron was required for Plk4 
to promote its own destruction. To test this hypothesis, we cre-
ated a mutant Plk4 in which both phosphorylation sites in the 
-TrCP destruction motif were mutated to alanine (Plk4AA; 
Fig. 2 C). Plk4AA and Plk4KD both showed a dramatic reduction 
in -TrCP binding, which is consistent with Plk4 autophosphory-
lation of the -TrCP destruction motif in promoting -TrCP 
binding (Fig. 2 E). However, in contrast to Plk4KD, Plk4AA was 
ubiquitinated (albeit at a reduced level compared with Plk4WT) 
in cells (Fig. 2 F) and was only about twofold more stable than 
Plk4WT (Fig. 2 D). This demonstrates that phosphorylation of 
the -TrCP destruction motif only plays a minor role in regulat-
ing the stability of Plk4 in these human cells.
The ubiquitination and degradation of Plk4AA (Fig. 2, 
D and F) suggested that phosphorylation of additional sites 
is required to promote Plk4’s destruction. Therefore, mass 
spectrometry (MS) was used to map additional in vitro auto-
phosphorylation sites on GST-Plk4WT (Fig. S3 A). A densely 
of Plk4KD caused centriole amplification in a 2.5-fold smaller 
proportion (23%) of cells (Fig. 1, E and F; and Fig. S1 B).
Surprisingly, the total level of Plk4KD protein was >10-
fold higher than that of Plk4WT (Fig. 1, B and C), and the level 
of Plk4KD at the centriole was >45-fold higher than that of 
Plk4WT (Fig. S1, D and E), implicating kinase activity of Plk4 as 
a determinant of its stability. To test this hypothesis, we created 
an ATP analogue-sensitive (AS) mutant of Plk4 (Bishop et al., 
2000). Plk4AS possesses a point mutation at a conserved gate-
keeper residue (L89G) that enlarges the ATP-binding pocket 
and allows the kinase to be selectively inhibited by the bulky 
ATP analogue 1NM-PP1 (Fig. 1 A). To characterize the Plk4AS 
allele, we expressed and purified recombinant WT, AS, and KD 
GST-Plk4 and tested the ability of the kinase to phosphorylate 
histone H1 in vitro. GST-Plk4WT phosphorylated itself (in cis or 
trans) and the substrate histone H1, whereas GST-Plk4KD lacked 
detectable activity (Fig. S2, A and B). In comparison with 
GST-Plk4WT, GST-Plk4AS exhibited an 2.5 reduction in phos-
phorylation of itself and an 10-fold reduction in phosphory-
lation of the histone H1 (Fig. S2, A and C), which are reductions 
comparable with that observed with a similar Plk1AS allele that 
was shown to compensate for the loss of endogenous Plk1 in 
cells (Burkard et al., 2007).
As expected, in vitro 1NM-PP1 inhibited the activity of 
GST-Plk4AS but not GST-Plk4WT (Fig. S2 C). Therefore, we 
created stable cell lines expressing Plk4AS-EYFP and examined 
Plk4’s stability and ability to promote centriole amplification 
in the presence or absence of the 1NM-PP1. In the absence 
of drugs Plk4AS was expressed at a low level that promoted 
centriole overduplication in 64% of cells, which is similar to 
that observed with Plk4WT (Fig. 1, D–F). In contrast, addition 
of 1NM-PP1 caused a dramatic increase in the abundance of 
Plk4AS and reduced centriole overduplication to the level ob-
served with Plk4KD (Fig. 1, D–F). This suggests that the activity 
of Plk4AS can be inhibited by 1NM-PP1 in vivo and confirms 
that Plk4 kinase activity regulates its own stability.
Figure 2. Phosphorylation of the -TrCP–
binding motif has a minor effect on the stability 
of mouse Plk4. (A) Cells were treated with or 
without the proteasome inhibitor MG132 for 
8 h and immunoblotted to determine the ex-
pression level of Plk4WT and Plk4KD. (B) Expres-
sion of Plk4WT-EYFP or Plk4KD-EYFP was induced 
for 24 h in cells constitutively expressing 
Plk4KD-Myc. The expression level of the Myc 
and EYFP-tagged Plk4 transgenes was subse-
quently determined by immunoblotting. (C) The 
Plk4AA mutant possesses two mutations that 
prevent phosphorylation of the -TrCP–binding 
motif (highlighted in green). (D) Immunoblot 
shows a modest increase in the stability of 
Plk4AA. (E) HEK 293 cells were cotransfected 
with Plk4-EYFP and Myc–-TrCP and treated 
with MG132 for 4 h. Plk4-EYFP was purified 
using GBP-coupled beads or beads alone, and 
protein complexes were analyzed by immuno-
blotting. (F) HEK 293 cells were cotrans-
fected with Plk4-EYFP and HA-ubiquitin and 
treated with MG132 for 4 h. Plk4-EYFP was 
purified using GBP-coupled beads or beads 
alone, and protein complexes were analyzed 
by immunoblotting.
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His-Plk424 was reduced by about a third (36%) compared with 
that of His-Plk4WT (Fig. 3 C). Together, these data demonstrate that 
Plk4 multiply autophosphorylates a 24-aa region (aa 282–305) 
and that this region is not required for kinase activity in vitro.
We next tested whether aa 282–305 were involved in reg-
ulating Plk4 stability in cells. Importantly, deletion of aa 282–
305 (Plk424) dramatically stabilized Plk4 (Fig. 3 D). Plk424 
induced centriole overduplication in 75% of cells, and such 
cells contained a mean of 17 centrioles per cell compared 
with about eight centrioles for cells expressing Plk4WT (Fig. 3, 
E–G). This suggests that Plk4 multiply autophosphorylates a 
24-aa phosphodegron (282–305) that is required to destabilize 
kinase-active Plk4.
To determine how phosphorylation contributes to the in-
stability of kinase-active Plk4, we created several Plk4 mutants 
that were defective in phosphorylation at specific sites within 
aa 282–305 (Fig. 4 A): Plk4AA contains two mutations in the 
phosphorylated region containing 13 phosphorylatable aa 
within a 24-aa stretch (282–305) was identified (Fig. S3, B and C). 
This region contains the previously identified -TrCP two-
phosphosite phosphodegron (Cunha-Ferreira et al., 2009; 
Rogers et al., 2009) and is part of a putative PEST domain 
(aa 272–311) previously proposed to destabilize human Plk4 
(Fig. 3 A; Yamashita et al., 2001). Nine peptides within the 
282–305 region were identified with multiple (up to four) 
phosphorylations, albeit the exact positions of those sites could 
not be identified with certainty because of the close pack-
ing of phosphorylatable amino acids (Fig. S3, B and C). We 
next tested whether Plk4 could autophosphorylate this 24-aa 
domain in vitro. GST-Plk4WT readily phosphorylated His-Plk4KD 
(aa 1–416), but His-Plk424 (lacking aa 282–305) accumulated 
42% less phosphorylation (Fig. 3 B). Furthermore, although 
kinase-active His-Plk4WT and His-Plk424 phosphorylated 
histone H1 with similar efficiency, autophosphorylation of 
Figure 3. Plk4 autophosphorylates a 24-aa 
region to promote its own destruction.  
(A) Schematic showing the localization of the 
24-aa region that is required for Plk4 to pro-
mote its own destruction. The alignment of this 
region, which is rich in potential phosphory-
lation sites (S/T residues), is shown. This puta-
tive -TrCP–binding motif is contained within 
this region and marked by a line. (B) GST-Plk4 
kinase assays were performed using His-Plk4KD 
(aa 1–416) as a substrate. GST-Plk4WT phos-
phorylates itself and His-Plk4KD, but note that 
phosphorylation of His-Plk4KD is reduced by the 
24 mutation. Coomassie-stained gel shows 
the purified protein, and the autoradiogram 
shows the incorporation of [32P]ATP. Assays 
were performed for 60 min, and activity was 
measured by scintillation counting. (C) His-Plk4 
(aa 1–416) kinase assay was performed using 
histone H1 as a substrate. Despite the fact that 
WT and 24 His-Plk4 have similar activity to-
ward histone H1, His-Plk424 displays reduced 
autophosphorylation. Coomassie-stained gel 
shows the purified protein, and autoradiogram 
shows the incorporation of [32P]ATP. Assays 
were performed for 60 min, and activity was 
measured by scintillation counting. (D) Immuno-
blot showing the relative expression levels of 
WT, AA, 24, and KD Plk4-EYFP. (E) Graph 
quantifying of the proportion of cells with more 
than four centrioles 48 h after induction of Plk4-
EYFP. (F) Graph quantifying the mean number 
of centrioles per cell in cells with more than 
four centrioles. Counting was performed 48 h 
after induction of Plk4-EYFP. (G) Immunofluores-
cence images acquired 48 h after Plk4-EYFP 
was induced. Insets depict an enlargement of 
centrioles. Red, SAS-6; green, Plk4-EYFP; blue, 
DNA. Bars, 10 µm. C, Coomassie. Bars rep-
resent the mean of at least three independent 
experiments with >280 cells per condition. 
Error bars represent the SEM.
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we favor the interpretation that Plk4 directly promotes its own 
destruction through autophosphorylation of a 13-site multi-
phosphodegron (Fig. 4 E). The multiphosphodegron possesses 
a conserved -TrCP–binding site previously implicated in regu-
lating the stability of Drosophila Plk4 (Cunha-Ferreira et al., 
2009; Rogers et al., 2009). A mutant of mouse Plk4 unable to be 
phosphorylated in the -TrCP–binding site (Plk4AA) exhibited 
dramatically reduced -TrCP binding; however, Plk4AA was 
ubiquitinated and only modestly stabilized in cells. In contrast, 
deletion of the entire 24-aa multiphosphodegron or mutation of 
all 13 phosphorylation sites in this region dramatically stabi-
lized Plk4, suggesting that autophosphorylated Plk4 interacts 
with additional SCF F box proteins or alternative E3 ubiqui-
tin ligases that are required for degradation. Surprisingly, we 
found that repression of -TrCP stabilized Plk4AA, indicating 
that SCF-TrCP still contributes to the destruction of this mutant 
(Fig. S3 D). Although we suspect that this arises from an in-
direct effect of -TrCP depletion, it is possible that the small 
amounts of -TrCP associated with Plk4AA still play a role in 
targeting the protein for destruction.
Because Plk4 phosphorylation occurs in dynamic equilib-
rium with counteracting phosphatases, we speculate that a re-
quirement for multisite phosphorylation to prime degradation is 
-TrCP phosphodegron, Plk4A1 possesses mutations in the 
seven most-conserved phosphorylation sites downstream of 
the -TrCP phosphodegron, Plk4A2 contains mutations in the 
-TrCP phosphodegron and five downstream phosphorylation 
sites, Plk4A3 has nine phosphorylation sites mutated, and Plk4A4 
has all 13 phosphorylation sites abolished. Expression of these 
mutants in cells revealed that Plk4 became progressively stabi-
lized as more phosphorylation sites were abolished (Fig. 4 A). 
The stability of the various Plk4 phosphorylation mutants 
closely mirrored their capacity to drive centriole overduplica-
tion in cells, with both the proportion of cells with supernumer-
ary centrioles and the numbers of centrioles per cell increasing 
as more phosphorylation sites were mutated (Fig. 4, B–D). 
These data imply that autophosphorylation within aa 282–305 
has an additive effect on promoting Plk4’s destruction and acts 
to self-limit Plk4 activity and centriole duplication in cells.
Together, our results show that Plk4’s kinase activity auto-
regulates Plk4 protein stability. Our data do not exclude the pos-
sibility that Plk4 activity regulates stability through additional 
proteins; for example, Plk4-induced activation of an unknown 
kinase may regulate Plk4 stability. However, we demonstrate 
that Plk4 is capable of autophosphorylating a region crucial for 
the kinase activity-dependent degradation of Plk4. Therefore, 
Figure 4. Phosphorylation of multiple sites is required for optimal Plk4 destruction. (A) Alignment showing the positions of the different phosphorylation 
mutations in Plk4. Immunoblot showing the relative expression levels of WT, AA, A1, A2, A3, A4, and KD Plk4-EYFP. (B) Graph quantifying of the propor-
tion of cells with more than four centrioles 48 h after induction of Plk4-EYFP. Uninduced samples (Tet) are shown for comparison. (C) Graph quantifying 
the mean number of centrioles per cell in cells with more than four centrioles. Counting was performed 48 h after induction of Plk4-EYFP. Uninduced 
samples are shown for comparison. (D) Immunofluorescence images acquired 48 h after Plk4-EYFP was induced. Insets depict an enlargement of centrioles. 
Red, SAS-6; green, Plk4-EYFP; blue, DNA. Bars, 10 µm. (E) A model for the autoregulation of Plk4 stability. Bars represent the mean of at least three inde-
pendent experiments with >300 cells per condition. Error bars represent the SEM.
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Staining was performed with antibodies SAS-6 (human anti–SAS-6; pro-
vided by A. Dammermann, Ludwig Institute for Cancer Research, San 
Diego, CA) and GTU-88 (mouse anti–-tubulin; 1:250; Abcam). YFP was 
visualized directly using a GFP filter set, the human SAS6 antibody was 
directly conjugated to Cy5 (Jackson ImmunoResearch Laboratories, Inc.), 
and GTU88 was stained with a secondary goat anti–mouse antibody 
conjugated to AMCA.
Immunofluorescence images were collected using an inverted micro-
scope (IX-70; Olympus) with a Deltavision Core system (Applied Precision) 
controlling an interline charge-coupled device camera (CoolSNAP; Roper 
Industries) driven by softWoRx software (Applied Precision). Images were 
collected using a 100× or 60× 1.4 NA oil objective (Olympus) at 0.2-µM 
z sections and subsequently deconvolved. Imaging was performed at room 
temperature, and maximum intensity 2D projections were assembled for 
each image using softWoRx. With the exception of the images in Fig. S1 E, 
EYFP exposure times were adjusted for each Plk4-EYFP mutant. Centriole 
numbers were determined by counting the number of structures that stained 
positive for both Plk4-EYFP and SAS-6. For quantitation of EYFP, signal in-
tensity at the centriole unconvolved 2D maximum-intensity projections was 
saved as unscaled 16-bit TIFF images. Signal intensity was determined 
using MetaMorph (MDS Analytical Technologies) by drawing a 20 × 20–
pixel box and a larger 25 × 25–pixel box around the centrosome. The 
integrated EYFP intensity in the smaller box was calculated by subtracting 
the mean fluorescence intensity in the area between the two boxes (mean 
background) from the mean GFP intensity in the smaller box and multiply-
ing by the area of the smaller box.
Protein purification
GBP was purified from Escherichia coli (strain Rosetta [DE3]) and covalently 
coupled to NHS-activated Sepharose 4 Fast Flow beads (GE Healthcare) at 
1 mg/ml as described previously (Rothbauer et al., 2008). Recombinant 
His-Plk4 (aa 1–416) was transformed in E. coli (strain Rosetta [DE3]), and 
protein expression was induced at 16°C for 18 h with 200 nM IPTG. 
Bacterial pellets were suspended in lysis buffer (50 mM Tris-HCl, pH 8.0, 
100 mM NaCl, 20 mM imidazole, 0.1% -mercaptoethanol, 0.1% NP-40, 
1 mM PMSF, and 1 µM LPC) and lysed by sonication after 1 mg/ml lyso-
zyme treatment on ice for 30 min. After centrifugation at 15,000 rpm 
(SA-600; Sorvall) for 30 min, the supernatant was incubated with pre-
washed nickel nitrilotriacetic acid beads (QIAGEN) for 1 h at 4°C. 
Beads were washed extensively in wash buffer (50 mM Tris-HCl, pH 8.0, 
500 mM NaCl, 20 mM imidazole, 0.1% -mercaptoethanol, 0.1% 
NP-40, 1 mM PMSF, and 1 µM LPC), and protein was eluted in elution buffer 
(50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 300 mM Imidazole, 0.1% 
-mercaptoethanol, and 0.1% NP-40). Proteins were dialyzed into a final 
buffer containing 50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 20 mM imidaz-
ole, and 0.1% -mercaptoethanol. Recombinant GST-Plk4 was expressed 
and purified from insect cells (High Five; Invitrogen) using the Bac-to-Bac 
expression system (Invitrogen). Infected cell pellets were suspended in lysis 
buffer (PBS supplemented with 2 mM MgCl2, 5 mM DTT, 10 nM micro-
cystin, 1 mM Na3V04, 250 U benzonase nuclease [Sigma-Aldrich], 1 mM 
PMSF, and 1 mM LPC) and lysed by sonication. After centrifugation at 
15,000 rpm (SA-600; Sorvall) for 30 min, the supernatant was supple-
mented with 110 mM KCL and 0.1% Triton X-100 and incubated with gluta-
thione Sepharose (GE Healthcare) for 1 h at 4°C. Beads were washed 
extensively in wash buffer (PBS supplemented with 1 mM DTT, 0.1% Triton 
X-100, 100 mM KCL, 1 mM PMSF, and 1 µM LPC), and protein was eluted 
in elution buffer (1× PBS supplemented with 40 mM reduced glutathione, 
50 mM Tris, pH 8.0, and 5 mM DTT).
In vitro kinase assays
In vitro kinase assays were performed at room temperature in 20 mM Tris, 
pH 7.5, 25 mM KCl, 10 mM MgCl2, 1 mM DTT, 5 µM Na3V04 in the pres-
ence of 50 µM ATP, and 100 µCi/ml [32P]ATP. 2 µg of substrate was incu-
bated with 1 µg purified GST-Plk4 or 2 µg His-Plk4 (aa 1–416). Kinase 
reactions were stopped with sample buffer and analyzed by SDS-PAGE. 
For quantification, individual bands were excised, and the incorporation of 
32P was quantified using a scintillation counter (Beckman Coulter). For 
 phosphatase treatment, GST-Plk4 was incubated with  phosphatase 
(New England Biolabs, Inc.) at 30°C for 30 min.
MS sample preparation
20 µg trichloroacetic acid–precipitated GST-Plk4WT was dissolved in 8 M 
urea and 100 mM Tris, pH 8.0, with a final volume of 25 µl. The protein 
was reduced in 5 mM TCEP (Fluka) for 20 min at room temperature and 
alkylated in 10 mM iodoacetamide (Sigma-Aldrich) for 15 min in the dark. 
Each sample was diluted fourfold with 100 mM Tris, pH 8.0, and CaCl2 
likely to provide a temporal delay to allow Plk4 to phosphory-
late critical substrates required for centriole duplication before 
its protein level is down-regulated. This could create a sensitive 
biological switch in which Plk4 can be rapidly destabilized once its 
activity reaches a certain threshold level. This autoregulatory 
feedback loop places Plk4 stability under direct control of its 
own activity and may form an important mechanism to limit 
normal centriole duplication to once per cell cycle.
Materials and methods
Constructs
The full-length mouse Plk4 open reading frame was cloned into a pcDNA5/
FRT/TO-based vector (Invitrogen) modified to contain a C terminus EYFP 
or Myc epitope tag. To create Plk4A1 and Plk4A4, two silent point mutations 
were introduced to create an NheI site at aa 225–226. A fragment of 
mouse Plk4 (aa 223–387) encoding the appropriate mutations was syn-
thesized (Genscript) and used to replace a corresponding NheI–XhoI frag-
ment in mouse Plk4. All other Plk4 mutants were generated by site-directed 
mutagenesis (QuickChange; Agilent Technologies). To create His-Plk4 
(aa 1–416), the first 416 aa of mouse Plk4 were amplified by PCR and 
cloned into a pET30 bacterial expression vector (EMD), which contains 
an N-terminal 6His tag. To create GST-Plk4, the mouse Plk4 open read-
ing frame was cloned into a pFastBac1 (Invitrogen)-based vector modified 
to contain an N terminus GST tag. pcDNA3 Myc–-TrCP and pcDNA3 
HA-ubiquitin plasmids were obtained from Addgene.
Cell culture
Cells were maintained at 37°C in a 5% CO2 atmosphere in DME contain-
ing 10% tetracycline-free FBS (Takara Bio Inc.), 100 U/ml penicillin, 
100 U/ml streptomycin, and 2 mM L-glutamine. DLD-1 cells were used in 
all experiments except in Fig. 2 (E and F), which used HEK 293 cells.
Generation of stable cell lines and siRNA treatment
RFP-tagged histone H2B (H2B-RFP) was introduced into Flp-In TRex-DLD-1 
parental cells (provided by S. Taylor, The University of Manchester, Man-
chester, England, UK) using retroviral delivery as described previously 
(Shah et al., 2004). Stable integrates were selected in 2 μg/ml puromy-
cin, and single clones were isolated using FACS (FACSVantage; BD). Sta-
ble, isogenic cell lines expressing Plk4-EYFP were generated using the 
FRT/Flp-mediated recombination as described previously (Tighe et al., 
2004). Expression of Plk4-EYFP was induced with 1 µg/ml tetracycline 
(Sigma-Aldrich). Flp-In TRex-DLD-1 H2B-RFP cells were used for all the ex-
periments except in Fig. 2 (E and F). Small molecules were used at the fol-
lowing final concentrations: nocodazole MG132 (EMD), 20 µM; 1NM-PP1 
(EMD), 10 µM. For siRNA treatment, 1.5 × 105 cells were plated in a 
6-well plate, and duplexed siRNAs were introduced using Oligofectamine 
(Invitrogen). siRNAs directed against -TrCP (5-GUGGAAUUUGUG-
GAACAUC-3) and GAPDH (5-UGGUUUACAUGAUCCAAUA-3) were 
purchased from Thermo Fisher Scientific. 24 h after transfection, tetra-
cycline was added to induce expression of Plk4-EYFP and cells harvested 
and processed for immunoblotting 24 h later.
Immunoblotting and immunofluorescence
To purify Plk4-YFP, cells were lysed in lysis buffer (10 mM Tris, pH 7.5, 
0.1% Triton X-100, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 50 mM 
NaF, 20 mM -glycerophosphate, 0.1 mM DTT, 200 nM microcystin, 
1 mM PMSF, and 1 µM leupeptin, pepstatin, and chymostatin [LPC]), soni-
cated, and soluble extracts were prepared. The supernatant was incu-
bated with beads alone or beads coupled to GFP-binding protein (GBP; 
Rothbauer et al., 2008). Beads were washed five times in lysis buffer, and 
protein complexes were analyzed by immunoblotting. For immunoblot 
analysis, protein samples were separated by SDS-PAGE, transferred onto 
nitrocellulose membranes (Bio-Rad Laboratories), and probed with anti-
bodies 4A6 (mouse anti-Myc; 1:1,000; Millipore), DM1A (mouse anti– 
-tubulin; 1:1,000), and YFP (mouse anti-GFP; 1:500; Roche). For 
immunofluorescence, cells were grown on hydrochloric acid–washed, 
poly-L-lysine (Sigma-Aldrich)–coated 18-mm glass coverslips and fixed in 
100% ice-cold methanol for 10 min. Cells were blocked in 2.5% FBS, 
200 mM glycine, and 0.1% Triton X-100 in PBS for 1 h. Antibody incuba-
tions were conducted in the blocking solution for 1 h. DNA was detected 
using DAPI, and cells were mounted in Prolong Antifade (Invitrogen). 
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was added to a final concentration of 1 mM. 0.8 µl trypsin (0.5 µg/µl; 
Promega) was added for an overnight digestion at 37°C. Samples were 
acidified with formic acid to a final concentration of 5% for MS analysis.
MS analysis
The tryptic digest was pressure loaded onto an equilibrated fused silica cap-
illary column containing 3 cm Aqua 5u C18 (Phenomenex) packed into a 
250-µm-i.d. capillary with a filtered union (UpChurch Scientific). Next, an 
equilibrated 100-µm-i.d capillary with a 5-µm pulled tip containing 10 cm of 
C18 material was attached to the filter union and placed in line with a qua-
ternary HPLC (1200; Agilent Technologies). Peptides were separated with a 
2-h organic gradient (Dix et al., 2008) and analyzed on an LTQ-Orbitrap as 
previously described (Lu et al., 2008), except one full Fourier transform scan 
mass spectrum (400–1,800 m/z; resolution of 60,000) was followed by 
nine data-dependent MS/MS acquired in the linear ion trap.
Analysis of MS data
The ms2 spectra data were extracted from the raw files using the publicly 
available RAW Xtractor (version 1.9.1). Ms2 spectra data were searched 
using the ProLuCID search algorithm (Xu, T., J.D. Venable, S. Kyu Park, 
D. Cociorva, B. Lu, L. Liao, J. Wohlschlegel, J. Hewel, and J.R. Yates III. 
2006. Human Proteome Organisation Fifth Annual World Congress. 
Abstr. S271) against a custom-made database containing the longest entry 
form of the mouse International Protein Index database (version 3.26) as-
sociated with each Ensembl gene identifier, resulting in a total of 22,833 
unique entries. Additionally, each of these entries was reversed and ap-
pended to the database for assessment of false-positive rates. In total, 
the search database contained 45,666 protein sequence entries (22,833 
real sequences and 22,833 decoy sequences). Searches allowed for the 
static modification of cysteine residues (57.02146 D; because of alkyla-
tion) and differential modification (79.9663 D; phosphorylation) on serine 
and threonine residues up to a maximum of four residues per peptide. 
In addition, full tryptic enzyme specificity was defined for searches with 
a mass tolerance set to 100 ppms for precursor mass and 600 ppm for 
product ion masses. The resulting ms2 spectra matches were assembled 
and filtered using DTASelect2 (version 2.0.27). For this analysis, modi-
fied and unmodified peptides were each individually evaluated using 
the DTASelect2 software. In each of these subgroups, the distribution of 
Xcorr and DeltaCN values for a direct (to the direct database) and decoy 
(reversed database) were separated by quadratic discriminant analysis. 
Spectral matches were retained with Xcorr and deltaCN values that pro-
duced a maximum peptide false-positive rate of 1% that was derived from 
the frequency of matches to the decoy reverse database (number of decoy 
database hits/number of filtered peptides identified × 100). This value 
is calculated by the DTASelect2 software. In addition, a minimum pep-
tide length of 6-aa residues was imposed. Such criteria resulted in the 
elimination of most decoy database hits. Modified peptides were further 
validated using Debunker (Lu et al., 2007).
Online supplemental material
Fig. S1 shows that kinase activity destabilizes centriole-localized Plk4. 
Fig. S2 shows that an AS mutant of recombinant Plk4 can be inhibited with 
the ATP analogue 1NM-PP1. Fig. S3 shows in vitro phosphorylation analy-
sis of recombinant GST-Plk4. Online supplemental material is available at 
http://www.jcb.org/cgi/content/full/jcb.200911102/DC1.
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